Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
June 05 2023 - 4:35PM
Business Wire
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced the
appointment of Dr. Zachariah (“Zach”) McIver as Vice President,
Clinical Development. An accomplished physician-scientist with more
than 15 years of experience in clinical research, Dr. McIver joins
Janux after serving as Amgen’s Executive Medical Director, where he
led cross-functional teams in the design, implementation, and
execution of clinical and correlative study strategies.
“Zach has extensive clinical research experience including
leading the clinical development to maximize the value of
bispecific T-cell engager assets across multiple hematologic and
solid tumor malignancies,” said David Campbell, Ph.D., President
and CEO of Janux Therapeutics. “At Janux, Zach will play a key role
in clinical development oversight as we advance our novel
immunotherapy programs through clinical trials.”
“We’re excited to have Zach join the team as his experience with
advanced T-cell engager programs will be especially important as we
continue to advance our drug candidates in clinical trials,” said
Wayne Godfrey, M.D., Chief Medical Officer at Janux.
“With TRACTr and TRACIr, Janux has built two very powerful
platforms designed to overcome the toxicity and efficacy
limitations of earlier generations of bispecific immunotherapies,”
said Dr. McIver. “I look forward to working with the team at Janux
to advance the Company’s deep portfolio of next-generation
bispecific immunotherapies to improve cancer treatment and help
more patients.”
A board-certified hematologist and physician-scientist, Dr.
McIver began his career specializing in hematological malignancies
and immunotherapy working as a principal investigator at the
Hematology Branch of the National Heart, Lung, and Blood Institute
(NHLBI) at the National Institute of Health (NIH). He played a key
role in developing novel small molecules targeting alloreactive
T-cells to prevent graft-versus-host-disease (GVHD) and established
a stem cell transplant program for racial minority populations at
the Wake Forest University School of Medicine. Dr. McIver also
served as an attending physician at Wake Forest in the
hematology/oncology department. Prior to this, he was an attending
physician and a research investigator in the department of
hematology/oncology at Tulane University School of Medicine.
Dr. McIver earned a B.S. in Physics and General Sciences from
the University of Oregon, a Doctor of Osteopathic Medicine (D.O.)
from Ohio University College of Osteopathic Medicine and a Ph.D. in
Molecular Medicine and Translational Sciences at the Wake Forest
University School of Medicine. He completed his internal medicine
residency at the Cleveland Clinic, and his clinical fellowship in
hematology and oncology at the NHLBI at the NIH. In addition, Dr.
McIver is an active member of professional societies such as the
American Society of Clinical Oncology, American Society of
Hematology, and American College of Physicians.
Janux’s TRACTr and TRACIr Pipeline
JANX008 is a TRACTr that targets epidermal growth factor
receptor (EGFR) and is being studied in a Phase 1 clinical trial
for the treatment of multiple solid cancers including colorectal
cancer, squamous cell carcinoma of the head and neck, non-small
cell lung cancer, and renal cell carcinoma. Janux’s first clinical
candidate, JANX007, is a TRACTr that targets prostate-specific
membrane antigen (PSMA) and is being investigated in a Phase 1
clinical trial in adult subjects with metastatic
castration-resistant prostate cancer (mCRPC). Janux’s TRACIr drug
candidate, JANX009, is designed for targeting both the programmed
death-ligand 1 (PD-L1) receptor as well as the costimulatory CD28
receptor on T cells and is being investigated in preclinical
studies for the treatment of solid tumors. Janux is also applying
its proprietary technology to develop a TRACTr designed to target
trophoblast cell surface antigen 2 (TROP2), a clinically validated
anti-tumor target that is overexpressed in various cancer types,
such as breast, lung, urothelial, endometrial, ovarian, prostate,
pancreatic, gastric, colon, head and neck, and glioma. In addition
to named programs, Janux is generating a number of unnamed TRACTr
and TRACIr programs for potential future development.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing
next-generation bispecific immunotherapies with the goal of
fighting cancers by killing tumor cells while allowing healthy
tissues to remain unharmed. Janux’s proprietary platforms develop
unique Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated
Immunomodulators (TRACIr) and support the building of a broad
pipeline of drugs designed to direct and guide the patient’s immune
system to eradicate tumors while minimizing safety concerns. The
company's innovative technology currently focuses on the
engineering of bispecific antibodies functional only in the tumor,
designed to provide safety advantages compared to earlier
generations of bispecific immunotherapies. Currently, Janux’s two
lead TRACTr compounds for PSMA and EGFR are in the clinic. For more
information, please visit www.januxrx.com and follow us on
LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, Janux’s ability to bring new
treatments to cancer patients in need, expectations regarding the
timing, scope and results of Janux’s development activities,
including its ongoing and planned clinical trials, the timing of
and plans for regulatory filings, the potential benefits of Janux’s
product candidates and platform technologies, and expectations
regarding the use of Janux’s platform technologies to generate
novel product candidates. Factors that may cause actual results to
differ materially include the risk that compounds that appear
promising in early research do not demonstrate safety and/or
efficacy in later preclinical studies or clinical trials, the risk
that Janux may not obtain approval to market its product
candidates, uncertainties associated with performing clinical
trials, regulatory filings and applications, risks associated with
reliance on third parties to successfully conduct clinical trials,
the risks associated with reliance on outside financing to meet
capital requirements, and other risks associated with the process
of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. You are urged to consider
statements that include the words “may,” “will,” “would,” “could,”
“should,” “believes,” “estimates,” “projects,” “promise,”
“potential,” “expects,” “plans,” “anticipates,” “intends,”
“continues,” “designed,” “goal,” or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties Janux
faces, please refer to Janux’s periodic and other filings with the
Securities and Exchange Commission, which are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and Janux assumes no obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005059/en/
Investors: Andy Meyer Janux Therapeutics
ameyer@januxrx.com (202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications
Inc. jessica@litldog.com (858) 344-8091
Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
From Apr 2023 to Apr 2024